


ent-Kaurane Diterpenes and Further Constituents from *Wedelia trilobata*by **Yin Qiang**^{a)}, **Dao-Lin Du**^{b)}, **Yan-Jun Chen**^{c)}, and **Kun Gao**^{*a)}^{a)} State Key Laboratory of Applied Organic Chemistry and College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, P. R. China
(phone: +86-931-8912592; fax: +86-931-8912582; e-mail: npchem@lzu.edu.cn)^{b)} School of Environment, Jiangsu University, Zhenjiang 212013, P. R. China^{c)} School of Biotechnology and Chemical Engineering, Ningbo Institute of Technology, Zhejiang University, Ningbo 315100, P. R. China

Two new *ent*-kaurane diterpenes, wedelidins A (**8**) and B (**9**), together with eighteen other constituents, including the sesquiterpenoids **1** and **2**, *ent*-kaurane diterpenes **3–7**, triterpenoids **10** and **11**, steroids **12–14**, and flavonoids **15–17** as well as benzene derivatives **18–20**, were isolated from the aerial parts of *Wedelia trilobata*. The structures of wedelidins A (**8**) and B (**9**) were elucidated by extensive spectroscopic analyses (including UV, IR, NMR, and MS). Furthermore, the structures of compounds **2** and **3** were confirmed by X-ray single-crystal diffraction analyses.

Introduction. – *Wedelia trilobata* L. (Asteraceae) is a perennial plant. In traditional herbal medicine, *W. trilobata* has been used for the treatment of fever and malaria in Vietnam [1]. Previous investigations revealed that the secondary metabolites from this plant mainly consisted of terpenoids [1–3], flavonoids [4], and polyacetylenes as well as steroids [5].

As part of our ongoing search for terpenoids and steroids from natural sources [6–8], we investigated the aerial parts of *W. trilobata* from a phytochemical viewpoint, which led to the isolation of the 20 secondary metabolites **1–20**, including the two sesquiterpenoids **1** and **2**, the seven *ent*-kaurane diterpenes **3–9**, the two triterpenoids **10** and **11**, the three steroids **12–14**, and the three flavonoids **15–17** as well as the three benzene derivatives **18–20**. Among them, compounds **8** and **9**, named wedelidin A and B, resp., are two new *ent*-kaurane diterpenes. Herein, we will report the isolation and structural elucidation of these isolates. In addition, the ¹³C-NMR data of the five known *ent*-kaurane diterpenes **3–7** were completely assigned here by 2D-NMR spectra (¹H,¹H-COSY, HSQC, and HMBC), and the structures of compounds **2** and **3** were further confirmed by X-ray single-crystal diffraction analyses.

Results and Discussion. – Wedelidin A (**8**) was obtained as a white powder. The negative-ion-mode ESI-MS showed a quasimolecular ion at *m/z* 463.1 ($[M-H]^-$), which, combined with analyses of ¹³C-NMR data and the DEPT experiment, indicated a molecular formula C₂₉H₃₆O₅. This hypothesis was also supported by the quasimolecular ion at *m/z* 487.2445 ($[M+Na]^+$) in the positive-ion-mode HR-ESI-MS, corresponding to 12 degrees of unsaturation. Its IR spectrum showed absorptions at 3347 (OH), 1708 (C=O), and 1567 and 1470 cm⁻¹ (aromatic C=C). The existence of a



cinnamate (= (2*E*)-3-phenylprop-2-enoate) ester function was supported by the following ¹H- and ¹³C-NMR data: δ (H) 6.47 (*d*, *J* = 15.9 Hz, 1 H), 7.70 (*d*, *J* = 15.9 Hz, 1 H), 7.37–7.39 (overlap, 3 H), and 7.52–7.54 (overlap, 2 H), and δ (C) 166.7 (*s*), 118.3 (*d*), 145.1 (*d*), 134.7 (*s*), 128.1 (*d*), 128.9 (*d*), and 130.3 (*d*) (Tables 1 and 2). Besides the above moiety, the remaining twenty C-atoms included a trisubstituted C=C bond (δ (H) 5.53 (*br. s*); δ (C) 137.1 (*d*) and 141.3 (*s*)), a COOH group (δ (C) 180.4 (*s*)), an O-bearing CH group (δ (H) 4.70 (*dd*, *J* = 4.2, 12.0 Hz); δ (C) 78.8 (*d*)), and an O-bearing CH₂ group (δ (H) 4.57 (*br. s*); δ (C) 75.1 (*t*)). Further analyses indicated a closely similar NMR pattern of compound **8** to that of (3 α)-3-(cinnamoyloxy)-*ent*-kaur-16-en-19-oic acid (**7**), suggesting the structure of an *ent*-kaurane diterpenoid for **8** [2]. The cinnamate ester moiety should be bonded to the position C(3) based on the HMBC from H–C(3) to C(1') (Fig. 1). The major difference in the NMR data between compounds **8** and **7** was that the signals of the above-described O-bearing CH₂ group and the trisubstituted C=C bond in ring *D* of **8** appeared instead of those of the exocyclic CH₂=C(16) moiety of **7**. The NMR data of ring *D* of **8** were also supported by the HMBC experiment (Fig. 1). The relative configuration of compound **8** was established by comparison of its NMR data with those of **7**. The H–C(3) signal of **8** appeared as *dd* (*J* = 4.2 and 12.0 Hz) with a closely similar coupling pattern to that observed for **7** (*dd*, *J* = 4.4 and 12.0 Hz) [2]. So, the cinnamate ester moiety should be α -oriented in compound **8**. Finally, the structure of wedelidin A (**8**) was elucidated as (3 α)-3-(cinnamoyloxy)-17-hydroxy-*ent*-kaur-15-en-19-oic acid.

Wedelidin B (**9**) was obtained as a white powder. Its positive-ion-mode HR-ESI-MS revealed a quasimolecular ion at *m/z* 463.2483 ($[M + H]^+$), suggesting a molecular

Table 1. ¹H-NMR Data (CDCl₃) of Compounds **8** and **9**. δ in ppm, *J* in Hz.

	8 ^{a)}	9 ^{b)}
CH ₂ (1)	2.03–2.05 (<i>m</i>), 0.99–1.12 (<i>m</i>)	2.03–2.06 (<i>m</i>), 1.10–1.12 (<i>m</i>)
CH ₂ (2)	2.45 (<i>q</i> , <i>J</i> = 12.0), 1.81 (overlap)	2.45 (<i>q</i> , <i>J</i> = 12.0), 1.80 (overlap)
H–C(3)	4.70 (<i>dd</i> , <i>J</i> = 4.2, 12.0)	4.70 (<i>dd</i> , <i>J</i> = 4.2, 12.0)
H–C(5)	1.17 (overlap)	1.15 (overlap)
CH ₂ (6)	1.88–1.91 (<i>m</i>), 1.70–1.73 (<i>m</i>)	1.88–1.92 (<i>m</i>), 1.71–1.75 (<i>m</i>)
CH ₂ (7)	1.93–1.96 (<i>m</i>), 1.09–1.11 (<i>m</i>)	1.99–2.02 (<i>m</i>), 1.14–1.18 (<i>m</i>)
H–C(9)	1.21–1.24 (<i>m</i>)	1.24–1.29 (<i>m</i>)
CH ₂ (11)	1.55–1.60 (overlap, 2 H)	1.55–1.60 (overlap, 2 H)
CH ₂ (12)	1.58 (overlap), 1.50 (overlap)	1.60 (overlap), 1.50 (overlap)
H–C(13)	2.62 (<i>br. s</i>)	3.06 (<i>br. s</i>)
CH ₂ (14)	1.89–1.91 (<i>m</i>), 1.50–1.54 (<i>m</i>)	2.06–2.09 (<i>m</i>), 1.47–1.51 (<i>m</i>)
H–C(15)	5.53 (<i>br. s</i>)	6.59 (<i>br. s</i>)
CH ₂ (17) or H–C(17)	4.57 (<i>br. s</i>)	9.75 (<i>s</i>)
Me(18)	1.35 (<i>s</i>)	1.34 (<i>s</i>)
Me(20)	1.09 (<i>s</i>)	1.09 (<i>s</i>)
H–C(2')	6.47 (<i>d</i> , <i>J</i> = 15.9)	6.47 (<i>d</i> , <i>J</i> = 16.2)
H–C(3')	7.70 (<i>d</i> , <i>J</i> = 15.9)	7.70 (<i>d</i> , <i>J</i> = 16.2)
H _o	7.52–7.54 (overlap, 2 H)	7.52–7.54 (overlap, 2 H)
H _m	7.37–7.39 (overlap, 2 H)	7.37–7.39 (overlap, 2 H)
H _p	7.37–7.39 (overlap)	7.37–7.39 (overlap)

^{a)} Measured at 300 MHz. ^{b)} Measured at 600 MHz.

Table 2. ^{13}C -NMR Data (CDCl_3) of Compounds 3–9. δ in ppm.

	3 ^{a)}	4 ^{a)}	5 ^{a)}	6 ^{a)}	7 ^{a)}	8 ^{b)}	9 ^{c)}
C(1)	41.1 (<i>t</i>)	40.7 (<i>t</i>)	38.8 (<i>t</i>)	38.8 (<i>t</i>)	38.9 (<i>t</i>)	38.8 (<i>t</i>)	39.7 (<i>t</i>)
C(2)	19.5 (<i>t</i>)	20.1 (<i>t</i>)	24.2 (<i>t</i>)	24.0 (<i>t</i>)	24.2 (<i>t</i>)	24.1 (<i>t</i>)	24.1 (<i>t</i>)
C(3)	38.2 (<i>t</i>)	38.2 (<i>t</i>)	78.7 (<i>d</i>)	78.8 (<i>d</i>)	79.0 (<i>d</i>)	78.8 (<i>d</i>)	78.6 (<i>d</i>)
C(4)	44.7 (<i>s</i>)	44.7 (<i>s</i>)	48.0 (<i>s</i>)	48.1 (<i>s</i>)	48.1 (<i>s</i>)	48.1 (<i>s</i>)	48.0 (<i>s</i>)
C(5)	57.5 (<i>d</i>)	46.6 (<i>d</i>)	56.5 (<i>d</i>)	56.4 (<i>d</i>)	56.5 (<i>d</i>)	56.1 (<i>d</i>)	55.9 (<i>d</i>)
C(6)	22.3 (<i>t</i>)	18.4 (<i>t</i>)	21.5 (<i>t</i>)	21.5 (<i>t</i>)	21.6 (<i>t</i>)	20.5 (<i>t</i>)	20.1 (<i>t</i>)
C(7)	41.7 (<i>t</i>)	29.7 (<i>t</i>)	39.5 (<i>t</i>)	39.5 (<i>t</i>)	39.5 (<i>t</i>)	39.1 (<i>t</i>)	38.0 (<i>t</i>)
C(8)	44.2 (<i>s</i>)	42.3 (<i>s</i>)	43.8 (<i>s</i>)	43.8 (<i>s</i>)	43.9 (<i>s</i>)	49.0 (<i>s</i>)	50.6 (<i>s</i>)
C(9)	55.6 (<i>d</i>)	158.5 (<i>s</i>)	55.2 (<i>d</i>)	55.1 (<i>d</i>)	55.2 (<i>d</i>)	47.4 (<i>d</i>)	46.1 (<i>d</i>)
C(10)	40.1 (<i>s</i>)	38.8 (<i>s</i>)	43.8 (<i>s</i>)	43.8 (<i>s</i>)	39.4 (<i>s</i>)	39.6 (<i>s</i>)	38.8 (<i>s</i>)
C(11)	18.4 (<i>t</i>)	114.9 (<i>d</i>)	18.5 (<i>t</i>)	18.5 (<i>t</i>)	18.5 (<i>t</i>)	19.0 (<i>t</i>)	18.8 (<i>t</i>)
C(12)	33.5 (<i>t</i>)	37.9 (<i>t</i>)	33.1 (<i>t</i>)	33.0 (<i>t</i>)	33.1 (<i>t</i>)	25.3 (<i>t</i>)	25.1 (<i>t</i>)
C(13)	44.3 (<i>d</i>)	41.2 (<i>d</i>)	43.9 (<i>d</i>)	43.9 (<i>d</i>)	43.8 (<i>d</i>)	41.5 (<i>d</i>)	37.8 (<i>d</i>)
C(14)	40.1 (<i>t</i>)	44.9 (<i>t</i>)	41.0 (<i>t</i>)	41.0 (<i>t</i>)	41.0 (<i>t</i>)	43.6 (<i>t</i>)	42.8 (<i>t</i>)
C(15)	49.4 (<i>t</i>)	50.3 (<i>t</i>)	48.8 (<i>t</i>)	48.7 (<i>t</i>)	48.8 (<i>t</i>)	137.1 (<i>d</i>)	161.0 (<i>d</i>)
C(16)	156.3 (<i>s</i>)	155.9 (<i>s</i>)	155.3 (<i>s</i>)	155.3 (<i>s</i>)	155.3 (<i>s</i>)	141.3 (<i>s</i>)	148.8 (<i>s</i>)
C(17)	103.7 (<i>t</i>)	105.5 (<i>t</i>)	103.3 (<i>t</i>)	103.3 (<i>t</i>)	103.3 (<i>t</i>)	75.1 (<i>t</i>)	189.4 (<i>d</i>)
C(18)	29.4 (<i>q</i>)	28.2 (<i>q</i>)	24.0 (<i>q</i>)	23.9 (<i>q</i>)	23.9 (<i>q</i>)	23.8 (<i>q</i>)	23.8 (<i>q</i>)
C(19)	184.0 (<i>s</i>)	183.3 (<i>s</i>)	180.7 (<i>s</i>)	180.4 (<i>s</i>)	180.6 (<i>s</i>)	180.4 (<i>s</i>)	180.3 (<i>s</i>)
C(20)	16.0 (<i>q</i>)	23.6 (<i>q</i>)	15.4 (<i>q</i>)	15.3 (<i>q</i>)	15.4 (<i>q</i>)	15.4 (<i>q</i>)	15.5 (<i>q</i>)
C(1')			167.7 (<i>s</i>)	167.7 (<i>s</i>)	166.8 (<i>s</i>)	166.7 (<i>s</i>)	166.7 (<i>s</i>)
C(2')			128.0 (<i>s</i>)	128.8 (<i>s</i>)	118.4 (<i>d</i>)	118.3 (<i>d</i>)	118.2 (<i>d</i>)
C(3')			138.0 (<i>d</i>)	137.4 (<i>d</i>)	145.1 (<i>d</i>)	145.1 (<i>d</i>)	145.2 (<i>d</i>)
Me(4') or C _{ipso}			15.7 (<i>q</i>)	14.4 (<i>q</i>)	134.5 (<i>s</i>)	134.7 (<i>s</i>)	134.4 (<i>s</i>)
Me–C(2') or C _o			20.6 (<i>q</i>)	12.0 (<i>q</i>)	128.1 (<i>d</i>)	128.1 (<i>d</i>)	128.1 (<i>d</i>)
C _m					128.8 (<i>d</i>)	128.9 (<i>d</i>)	128.9 (<i>d</i>)
C _p					130.3 (<i>d</i>)	130.3 (<i>d</i>)	130.3 (<i>d</i>)

^{a)} Measured at 100 MHz. ^{b)} Measured at 75 MHz. ^{c)} Measured at 150 MHz.




Fig. 1. Key HMBCs (H → C) of compound 8

formula $\text{C}_{29}\text{H}_{34}\text{O}_5$, which indicated 13 degrees of unsaturation. The IR spectrum showed absorptions at 3375 (OH), 1710 ($\text{C}=\text{O}$), and 1662 and 1453 cm^{-1} (aromatic $\text{C}=\text{C}$). The presence of a cinnamate ester moiety was supported by NMR data (Tables 1 and 2). Besides this ester moiety, the remaining twenty C-atoms included a trisubstituted $\text{C}=\text{C}$ bond ($\delta(\text{H})$ 6.59 (br. *s*); $\delta(\text{C})$ 161.0 (*d*) and 148.8 (*s*)), a COOH group ($\delta(\text{C})$ 180.3 (*s*)), an aldehyde $\text{C}=\text{O}$ group ($\delta(\text{C})$ 189.4 (*d*)), and an O-bearing CH group ($\delta(\text{H})$ 4.70 (*dd*, $J = 4.8, 12.0\text{ Hz}$); $\delta(\text{C})$ 78.6 (*d*)). Further analyses demonstrated

that compound **9** showed a closely similar NMR pattern to that of **8**, besides the existence of a CHO instead of an O-bearing CH₂ group, indicating that compound **9** was an *ent*-kaurane diterpenoid. Based on the HMBCs C(17) ($\delta(C)$ 189.4 (s))/H–C(13) and H–C(15), the position of the CHO group should be assigned to CH(17). The α -orientation of the cinnamate ester moiety of **9** was established by comparison of the H–C(3) coupling pattern (*dd*, $J=4.8$ and 12.0 Hz) with that of **8** (*dd*, $J=4.2$ and 12.0 Hz). Thus, the structure of wedelidin B (**9**) was determined as (3 α)-3-(cinnamoyloxy)-17-oxo-*ent*-kaur-15-en-19-oic acid.

In addition to the above described two new *ent*-kaurane diterpenes **8** and **9**, 18 secondary metabolites were isolated. Based on the spectroscopic analyses and comparison with the literature data, they were determined as ivalin (**1**) [9], wedeliatrilolactone B (**2**) [10], *ent*-kaur-16-en-19-oic acid (**3**) [11], *ent*-kaura-9(11),16-dien-19-oic acid (**4**) [12], (3 α)-3-(angeloyloxy)-*ent*-kaur-16-en-19-oic acid (**5**) [13], (3 α)-3-(tiglinoyloxy)-*ent*-kaur-16-en-19-oic acid (**6**) [2], (3 α)-3-(cinnamoyloxy)-*ent*-kaur-16-en-19-oic acid (**7**) [2], β -friedelinol (**10**) [14], friedelin (**11**) [15], stigmasterol (**12**) [16], (7 α)-7-hydroxystigmasterol (**13**) [17], (3 β)-3-hydroxystigmasta-5,22-dien-7-one (**14**) [18], 3-hydroxy-6-methoxychromen-4-one (**15**) [19], apigenin (**16**) [20], diosmetin (**17**) [21], benzeneacetic acid 2-phenylethenyl ester (**18**) [22], isocinnamic acid (**19**) [23], and 4-methoxycatechol (**20**) [24]. Among these isolates, compounds **1**, **4**, and **11–20** are reported as secondary metabolites from *W. trilobata* for the first time. The structures of compounds **2** and **3** were further confirmed by an X-ray single-crystal diffraction experiment for the first time (Fig. 2). Crystals of **2** and **3** were obtained from a solution of CHCl₃/MeOH 1:1. The crystallographic data have been deposited with the *Cambridge Crystallographic Data Centre*¹⁾.




Fig. 2. X-Ray single-crystal structures of compounds **2** and **3**. Arbitrary atom numbering.

¹⁾ CCDC-778708 (for **2**) and 782281 (for **3**) contain the supplementary crystallographic data for this article. These data can be obtained free of charge from the *Cambridge Crystallographic Data Centre* via www.ccdc.cam.ac.uk/data_request/cif.

This work was supported by the *Basic Research Program (973 Program) of China* (No. 2007CB108903), the *National Science Foundation of China* (No. 20972062 and No. 30970556), and the *111 Project*.

Experimental Part

General. Column chromatography (CC): silica gel (SiO₂, 200–300 mesh; *Qingdao Marine Chemical Factory*, Qingdao, P. R. China). TLC: SiO₂ GF₂₅₄ (10–40 μm, *Qingdao Marine Chemical Factory*); detection at 254 nm, and by heating after spraying with 98% H₂SO₄ soln./EtOH 5:95 (v/v). Optical rotations: *Perkin-Elmer-341* polarimeter; in MeOH at 25°. UV Spectra: *NewCentury-Pgeneral-T6* spectrophotometer; λ_{max} (log ε) in nm. IR Spectra: *Nicolet-Nexus-670* FT-IR spectrometer; with KBr pellets; $\tilde{\nu}$ in cm⁻¹. NMR Spectra: *Varian-Inova-300*, *Bruker-Avance-III-400*, and *Varian-Inova-600* instruments; δ in ppm rel. to Me₄Si as internal standard, *J* in Hz. MS: *Bruker-Esquire-6000* (ESI) and *Bruker-Apex-II* (HR-ESI) instrument; in *m/z*.

Plant Material. The plant material was collected in Haikou City, Hainan Province, China, in June 2008 and authenticated by advanced lab assistant *Qiong-Xin Zhong* of the College of Biology, Hainan Normal University. A voucher specimen (20070805) was deposited with the College of Chemistry and Chemical Engineering, Lanzhou University.

Extraction and Isolation. The air-dried whole plant of *W. trilobata* (4600.3 g) was powdered and extracted with 95% EtOH (15 l) three times (each for 7 d) at r.t. and the soln. concentrated to give a crude extract (671.2 g), which was suspended in H₂O (2.5 l) and then extracted with petroleum ether (60–90°; 3 × 2.5 l) and CHCl₃ (4 × 2.0 l) successively. The petroleum ether extract (180.1 g) was subjected to CC (SiO₂, petroleum ether/AcOEt 40:1, 20:1, 10:1, 5:1, 2:1, and 0:1): *Fractions 1–6* (monitored by TLC). *Fr. 1* (60.7 g) was repeatedly applied to CC (SiO₂, petroleum ether/AcOEt 50:1 → 10:1): **3** (10.8 g) and **4** (68.6 mg). *Fr. 2* (10.5 g) was also applied to CC (SiO₂, petroleum ether/AcOEt 25:1): **5** (2.1 mg) and a crude crystalline product. The latter was recrystallized from petroleum ether/AcOEt 1:1: **9** (3.8 g). *Fr. 3* (20.4 g) was subjected to repeated CC (SiO₂, petroleum ether/AcOEt 20:1 → 5:1): *Frs. 3.1* and *3.2*. *Fr. 3.1* (10.2 g) was further purified by CC (SiO₂, petroleum ether/AcOEt 10:1): **6** (8.2 mg), **7** (20.6 mg), and **8** (4.6 mg). *Fr. 3.2* (0.6 g) was subjected to prep. TLC (CHCl₃/AcOEt 15:1): **10** (4.7 mg) and **11** (33.2 mg). *Fr. 4* (3.8 g) was applied to CC (SiO₂, petroleum ether/AcOEt 10:1 → 2:1): *Frs. 4.1–4.3*. *Fr. 4.1* (1.0 g) was further subjected to CC (SiO₂, CHCl₃/AcOEt 15:1 → 5:1): **13** (2.9 mg), **15** (6.8 mg), and **17** (9.2 mg). *Fr. 4.2* (1.8 g) was also further purified by CC (SiO₂, CHCl₃/AcOEt 10:1 → 2:1): **1** (1.1 mg), **2** (4.2 mg), and **12** (6.2 mg). *Fr. 5* (1.6 g) was subjected to repeated CC (SiO₂, CHCl₃/AcOEt 15:1 → 3:1): **16** (8.3 mg), **19** (10.4 mg), and **20** (5.1 mg). The CHCl₃ extract (5.6 g) was subjected to repeated CC (SiO₂, CHCl₃/acetone 50:1 → 2:1): *Frs. a–d* (by TLC). *Fr. c* (1.9 g) was further purified with CC (SiO₂, CHCl₃/CH₃OH 20:1): **14** (3.0 mg) and **18** (5.6 mg).

Wedelidin A (= (3α)-3-(Cinnamoyloxy)-17-hydroxy-ent-kaur-15-en-19-oic Acid = (3α)-17-Hydroxy-3-[[(2E)-1-oxo-3-phenylprop-2-en-1-yl]oxy]-ent-kaur-15-en-19-oic Acid; **8**): White amorphous powder. [α]_D²⁵ = –8.2 (c = 0.1, MeOH). UV (MeOH): 207 (3.25), 274 (3.37). IR (KBr): 3347, 2962, 2931, 2868, 1708, 1567, 1470, 1311, 812. ¹H-NMR (300 MHz, CDCl₃): *Table 1*. ¹³C-NMR (75 MHz, CDCl₃): *Table 2*. HR-ESI-MS: 487.2445 ([M + Na]⁺, C₂₉H₃₆NaO₅⁺; calc. 487.2455).

Wedelidin B (= (3α)-3-(Cinnamoyloxy)-17-oxo-ent-kaur-15-en-19-oic Acid = (3α)-17-Oxo-3-[[(2E)-1-oxo-3-phenylprop-2-en-1-yl]oxy]-ent-kaur-15-en-19-oic Acid; **9**): White amorphous powder. [α]_D²⁵ = –6.1 (c = 0.1, MeOH). UV (MeOH): 215 (3.11), 275 (3.09). IR (KBr): 3375, 2925, 1710, 1662, 1453, 1070, 1026, 768. ¹H-NMR (600 MHz, CDCl₃): *Table 1*. ¹³C-NMR (150 MHz, CDCl₃): *Table 2*. HR-ESI-MS: 463.2483 ([M + H]⁺, C₂₉H₃₅O₅⁺; calc. 463.2479).

REFERENCES

- [1] Q. T. That, J. Jossang, A. Jossang, P. P. N. Kim, G. Jaureguiberry, *J. Org. Chem.* **2007**, 72, 7102.
- [2] F. Bohlmann, J. Ziesche, R. M. King, H. Robinson, *Phytochemistry* **1981**, 20, 751.
- [3] T. H. Nguyen, N. V. Huynh, T. Q. Ton, K. P. P. Nguyen, *Tap Chi Hoa Hoc* **2006**, 44, 91.

- [4] H. Zhu, R. J. Ma, S. T. Wu, Q. Y. Pang, *Food Sci.* **2009**, *30*, 52.
- [5] M. L. Wu, D. Z. Zhang, *Pharm. Today* **2008**, *18*, 21.
- [6] J. J. Chen, Z. M. Li, K. Gao, J. Chang, X. J. Yao, *J. Nat. Prod.* **2009**, *72*, 1128.
- [7] C. M. Liu, H. X. Wang, S. L. Wei, K. Gao, *Helv. Chim. Acta* **2008**, *91*, 308.
- [8] H. X. Wang, C. M. Liu, Q. Liu, K. Gao, *Phytochemistry* **2008**, *69*, 2088.
- [9] G. Topçu, S. Öksüz, H. L. Shieh, G. A. Cordell, G. M. Pezzuto, B. J. Candan, *Phytochemistry* **1993**, *33*, 407.
- [10] D. T. Ferreira, A. R. Levorato, T. D. J. Faria, M. G. De Carvalho, R. Braz-Filho, *Nat. Prod. Lett.* **1994**, *4*, 1.
- [11] W. Herz, P. Kulanthaivel, *Phytochemistry* **1984**, *23*, 2271.
- [12] S. F. Farag, H. A. Hassanean, M. A. Makboul, N. A. El-Emary, M. Niwa, *Bull. Pharm. Sci., Assiut Univ.* **1998**, *21*, 81.
- [13] R. Batista, E. Chiari, A. Braga de Oliveira, *Planta Med.* **1999**, *65*, 283.
- [14] J. Q. Liu, J. M. Wu, X. L. Kou, Q. Hong, *J. Chin. Med. Mater.* **2008**, *31*, 1505.
- [15] D. D. Chiozem, H. Trinh-Van-Dufat, J. D. Wansi, D. C. Mbazona, V. S. Fannang, E. Seguin, F. Tillequin, J. Wandji, *Chem. Pharm. Bull.* **2009**, *57*, 1119.
- [16] S. C. Pu, Y. Q. Guo, W. Y. Gao, *Chin. Tradit. Herb. Drugs* **2009**, *40*, 363.
- [17] Y. H. Lan, H. Y. Wang, C. C. Wu, S. L. Chen, C. L. Chang, F. R. Chang, Y. C. Wu, *Chem. Pharm. Bull.* **2007**, *55*, 1597.
- [18] L. H. Yan, L. Z. Xu, Z. M. Zou, S. L. Yang, *Chin. Tradit. Herb. Drugs* **2007**, *38*, 340.
- [19] P. Pfeiffer, H. Oberlin, E. Konermann, *Ber. Dtsch. Chem. Ges. (B Series)* **1925**, *58*, 1947.
- [20] Q. Li, Q. M. Xu, L. L. Hao, B. F. Lu, S. L. Yang, X. R. Li, *Chin. Tradit. Herb. Drugs* **2009**, *40*, 369.
- [21] G. N. K. Kumari, L. J. M. Rao, N. S. P. Rao, *Proc. Indian Acad. Sci., Chem. Sci.* **1986**, *97*, 171.
- [22] I. Yukhnovski, A. F. Nazir, M. Sakhatchieva, J. Kaneti, I. Binev, *Izv. Khim.* **1981**, *13*, 269.
- [23] F. B. L. Warnaar, *Phytochemistry* **1984**, *23*, 1049.
- [24] P. Sampson, M. Crook, A. Piorko, *J. Heterocycl. Chem.* **1994**, *31*, 1011.

Received August 10, 2010